Fig. 2

Performance of potential 5hmC markers for identification of CAD patients and non-CAD patients. a Principle component analysis (PCA) plot of 5hmC FPKM in cfDNA from CAD and NCA samples. b Receiver operating characteristic (ROC) curve of the classification model with potential 5hmC markers and clinical indicators, including LDL-C, TC, cTnI, MYO, and CK-MB in the validating set (19 NCA vs. 37 CAD samples). The true positive rate (sensitivity) is plotted in function of the false positive rate (specificity). c KEGG functional enrichment analysis of genes with significant 5hmC increase in CAD samples. d KEGG functional enrichment analysis of genes with significant 5hmC decrease in CAD samples. e Top enriched known transcription factor binding motifs detected in DhMRs in CAD and NCA groups (left: 5hmC gain; right: 5hmC loss). Motif information was obtained from the Homer motif database. The value in parenthesis represents the percentage of target sequences enriched with the binding motif of the indicated transcription factor. CAD coronary artery disease, NCA normal coronary artery, TSS transcription start site, TTS transcription termination site, FPKM fragments per kilobase of transcript per million mapped reads, AUC area under the curve, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, cTnI cardiac troponin I, MYO myoglobin, CK-MB MB isoenzyme of creatine kinase, DhMRs differentially hydroxy methylated regions, PAX5 paired box protein Pax-5, TEAD4 transcriptional enhancer factor TEF-3, transcriptional enhancer factor TEF-5, SOX9 SRY-type box 9, HIF-1b hypoxia-inducible factor 1 beta, Smad3 mothers against decapentaplegic homolog 3